Insights Into Imaging

Journal Title：Insights Into Imaging

Insights into Imaging (I3) is a peer-reviewed open access journal published under the brand SpringerOpen. All content published in the journal is freely available online to anyone, anywhere!

I3 continuously updates scientific knowledge and progress in best-practice standards in radiology through the publication of original articles and state-of-the-art reviews and opinions, along with recommendations and statements from the leading radiological societies in Europe.

Founded by the European Society of Radiology (ESR), I3 creates a platform for educational material, guidelines and recommendations, and a forum for topics of controversy.

A balanced combination of review articles, original papers, short communications from European radiological congresses and information on society matters makes I3 an indispensable source for current information in this field.

I3 is owned by the ESR, however authors retain copyright to their article according to the Creative Commons Attribution License (see Copyright and License Agreement). All articles can be read, redistributed and reused for free, as long as the author of the original work is cited properly.

The open access fees (article-processing charges) for this journal are kindly sponsored by ESR for all Members.

The journal went open access in 2012, which means that all articles published since then are freely available online.

Insights into Imaging (I3) 是 SpringerOpen 品牌下出版的同行評審開放獲取期刊。期刊上發表的所有內容均可在線免費供任何人、任何地方使用！

I3 通過發表原創文章和最新評論和觀點以及歐洲領先放射學會的建議和聲明，不斷更新科學知識和放射學最佳實踐標準的進展。

I3 由歐洲放射學會 (ESR) 創立，為教育材料、指南和建議以及爭議主題論壇創建了一個平臺。

評論文章、原創論文、歐洲放射學大會的簡短通訊和社會事務信息的平衡組合使 I3 成為該領域最新信息的不可或缺的來源。

I3 歸 ESR 所有，但作者根據知識共享署名許可保留其文章的版權（請參閱版權和許可協議）。所有文章均可免費閱讀、重新分發和重復使用，只要正確引用原作者即可。

本期刊的開放獲取費用（文章處理費）由 ESR 為所有會員提供贊助。

本期刊于 2012 年開放獲取，這意味著自那時起發表的所有文章均可在線免費獲取。

Insights Into Imaging創刊于2010年，由Springer Berlin Heidelberg出版商出版，收稿方向涵蓋Medicine - Radiology, Nuclear Medicine and Imaging全領域，此刊是該細分領域中屬于非常不錯的SCI期刊，在行業細分領域中學術影響力較大，專業度認可很高，所以對原創文章要求創新性較高，如果您的文章質量很高，可以嘗試。平均審稿速度 13 Weeks ，影響因子指數4.1，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。